Ipamorelin/CJC-1295 vs Tesamorelin — GH Secretagogue Comparison UK 2026 | Daxer Labs

Tesamorelin and Ipamorelin/CJC-1295 are two of the most widely studied GH secretagogue peptides in current research, and both sit at the centre of Daxer Labs' UK catalogue. They work through related but distinct mechanisms, which makes the choice between them a common question for researchers designing a new protocol. This comparison breaks down how each compound works, what the research literature says, and the practical differences that matter when selecting a compound for a study.

Research use only: Daxer Labs supplies Tesamorelin and Ipamorelin/CJC-1295 strictly for laboratory research and analytical purposes. This article is an educational comparison of published research characteristics, not guidance for human or animal use.

What Are GH Secretagogues?

Growth hormone secretagogues are a class of peptides studied for their ability to stimulate the pituitary gland's release of growth hormone through different receptor pathways. Two main mechanisms dominate current research: GHRH (growth hormone-releasing hormone) analogues, such as Tesamorelin, and GHRP/ghrelin-mimetic compounds like Ipamorelin, which are often studied in combination with CJC-1295 — itself a GHRH analogue with an extended half-life.

Tesamorelin: Mechanism & Research Profile

• Class: GHRH (growth hormone-releasing hormone) analogue

• Mechanism: Binds GHRH receptors in the pituitary, stimulating a natural pulsatile release of growth hormone

• Notable structural feature: A stabilising N-terminal modification that gives it greater resistance to enzymatic degradation than earlier GHRH analogues such as Sermorelin

• Commonly studied in relation to: Visceral fat metabolism and body composition research

• Supplied by Daxer Labs as: Tesamorelin 10mg, HPLC-verified to 98%+ purity

Ipamorelin/CJC-1295: Mechanism & Research Profile

• Class: Combination of a GHRP/ghrelin-mimetic (Ipamorelin) and a GHRH analogue (CJC-1295, no DAC)

• Mechanism: Ipamorelin selectively stimulates growth hormone release via the ghrelin receptor with minimal effect on cortisol or prolactin; CJC-1295 (no DAC) complements this by extending GHRH receptor stimulation

• Notable structural feature: The 'no DAC' formulation has a shorter half-life than DAC-modified CJC-1295, making pulsatile release patterns easier to study

• Commonly studied in relation to: Combined GH-axis research and comparative secretagogue studies

• Supplied by Daxer Labs as: Ipamorelin/CJC-1295 (no DAC), sold as a combined vial

Head-to-Head Comparison

• Receptor pathway: Tesamorelin acts on the GHRH receptor alone; Ipamorelin/CJC-1295 combines ghrelin-receptor and GHRH-receptor activity

• Specificity: Ipamorelin is noted in the literature for high receptor selectivity with minimal off-target hormone effects

• Half-life: Tesamorelin has a short half-life typical of GHRH analogues; CJC-1295 (no DAC) is also short-acting compared to its DAC-modified counterpart, while Ipamorelin's half-life is measured in minutes

• Typical research focus: Tesamorelin is more frequently referenced in visceral fat and metabolic studies; Ipamorelin/CJC-1295 is more frequently referenced in broader GH-axis and pulsatility research

• Format supplied by Daxer Labs: Both are lyophilised powders requiring reconstitution with bacteriostatic water before use

Which Should Researchers Choose?

The right compound depends entirely on the research question. Studies focused specifically on visceral fat metabolism or the Tesamorelin literature base tend to use Tesamorelin directly, since it has the largest published body of comparative data for that application. Studies examining broader GH-axis stimulation, receptor selectivity, or pulsatile release patterns often use Ipamorelin/CJC-1295 because the combination allows researchers to isolate ghrelin-receptor effects from GHRH-receptor effects. Some comparative protocols use both compounds side by side precisely because their mechanisms differ.

Quality & Sourcing Considerations

Mechanism aside, batch purity is what actually determines whether comparative research data is reliable. Daxer Labs manufactures in Switzerland and verifies every batch of Tesamorelin and Ipamorelin/CJC-1295 to a minimum of 98% purity by HPLC, with an independent Certificate of Analysis including full chromatographic data supplied for every order. For any comparison study, using two compounds from the same verified source reduces a major source of variability between arms of a protocol.

FAQs

Is Ipamorelin/CJC-1295 the same as Tesamorelin?

No. They are structurally distinct. Tesamorelin is a single GHRH analogue, while Ipamorelin/CJC-1295 is a combination of a ghrelin-receptor agonist (Ipamorelin) and a separate GHRH analogue (CJC-1295, no DAC).

Which has more published research, Tesamorelin or Ipamorelin?

Tesamorelin has a larger clinical research base, particularly around visceral fat metabolism, as it has been studied in that context for longer. Ipamorelin and CJC-1295 have a growing but comparatively smaller published literature.

Can Tesamorelin and Ipamorelin/CJC-1295 be studied together in the same protocol?

Some comparative research protocols use both compounds in parallel arms specifically to compare GHRH-only stimulation against combined ghrelin/GHRH stimulation, though protocol design is always study-specific.

What purity does Daxer Labs guarantee for both compounds?

Both Tesamorelin and Ipamorelin/CJC-1295 are verified to a minimum of 98% purity by HPLC, with most batches exceeding 99.5%, confirmed by an independent Certificate of Analysis.

Does Daxer Labs ship both peptides UK-wide?

Yes, Daxer Labs ships Tesamorelin and Ipamorelin/CJC-1295 to research addresses across the UK, with tracked, cold-chain delivery and full CoA documentation.

Compare and Source Both Peptides from Daxer Labs

Whichever mechanism your protocol calls for, Daxer Labs supplies both Tesamorelin 10mg and Ipamorelin/CJC-1295 (no DAC), each HPLC-verified with a full Certificate of Analysis and shipped UK-wide from our Swiss manufacturing facility.